These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 36770884)

  • 1. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
    Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
    Webb T; Craigon C; Ciulli A
    Bioorg Med Chem Lett; 2022 May; 63():128653. PubMed ID: 35257896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.
    Giardina SF; Valdambrini E; Warren JD; Barany F
    Curr Cancer Drug Targets; 2021; 21(4):306-325. PubMed ID: 33535953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer.
    Rutherford KA; McManus KJ
    Mol Cancer Ther; 2024 Apr; 23(4):454-463. PubMed ID: 38205881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
    Xie H; Zhang C
    Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degraders upgraded: the rise of PROTACs in hematological malignancies.
    Casan JML; Seymour JF
    Blood; 2024 Mar; 143(13):1218-1230. PubMed ID: 38170175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
    Tomaselli D; Mautone N; Mai A; Rotili D
    Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
    Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
    Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.
    Bhole RP; Kute PR; Chikhale RV; Bonde CG; Pant A; Gurav SS
    Bioorg Chem; 2023 Oct; 139():106720. PubMed ID: 37480814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies.
    Sincere NI; Anand K; Ashique S; Yang J; You C
    Molecules; 2023 May; 28(10):. PubMed ID: 37241755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.